Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Mabxience
Deal Size : Undisclosed
Deal Type : Partnership
Teva Expands Partnership with mAbxience for Additional Oncology Biosimilar
Details : mAbxience will lead the development and production of an anti PD-1 biosimilar and Teva will manage regulatory approvals and oversee commercialization of this oncology treatment.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 10, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Mabxience
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : n.c.a. 177-Lu
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : CPDC Centre for Probe Development and Commercialization
Deal Size : Inapplicable
Deal Type : Inapplicable
Isotopia and CPDC Successfully Deliver First Doses of n.c.a. Lu-177 to North American Customers
Details : 177Lu n.c.a (No-carrier-added Lutetium-177) is a very versatile isotope, and worldwide numerous clinical trials are being held, studying the effects of this isotope, used radiometal for targeted radiotherapy.
Product Name : n.c.a. 177-Lu
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 06, 2022
Lead Product(s) : n.c.a. 177-Lu
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : CPDC Centre for Probe Development and Commercialization
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NT219,Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Menashe Bar-Eli
Deal Size : Undisclosed
Deal Type : Collaboration
Purple Biotech Expands Research Collaboration in Immuno-Oncology in Combination with NT219
Details : This collaboration will evaluate the potential efficacy of the combination of NT219, a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3, and immuno-oncology drugs, such as anti-CTLA4 or anti-PD1/PDL1 antibodies.
Product Name : NT219
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 26, 2021
Lead Product(s) : NT219,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Menashe Bar-Eli
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : n.c.a. 177-Lu
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Seibersdorf Labor GmbH
Deal Size : Undisclosed
Deal Type : Collaboration
Isotopia Molecular Imaging and Seibersdorf Labor GmbH Announce Production Agreement for 177Lu n.c.a.
Details : Seibersdorf Labor, a GMP Contract manufacturing of radiopharmaceuticals, a global leader in the development, production, and commercialization of radiopharmaceuticals, will produce 177Lu n.c.a in collaboration with Isotopia Molecular Imaging for distribu...
Product Name : n.c.a. 177-Lu
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 18, 2021
Lead Product(s) : n.c.a. 177-Lu
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Seibersdorf Labor GmbH
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : CM-24,Paclitaxel,Nivolumab
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase 1/2 clinical trial will evaluate CM24, a monoclonal antibody targeting CEACAM1, in combination with nivolumab (Opdivo®) in patients with advanced non-small cell lung cancer.
Product Name : CM-24
Product Type : Antibody
Upfront Cash : Inapplicable
September 11, 2020
Lead Product(s) : CM-24,Paclitaxel,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Namodenoson,Nivolumab,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Namodenoson may create powerful combination treatment with checkpoint inhibitors.
Product Name : CF102
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 24, 2020
Lead Product(s) : Namodenoson,Nivolumab,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COM902,COM701,Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : China Patent titled "Anti-TIGIT Antibodies, Anti-PVRIG Antibodies and Combinations Thereof," relates to the composition of matter of COM902, alone or in combination with a second antibody targeting an immune checkpoint, including PD-1 and PVRIG.
Product Name : COM902
Product Type : Antibody
Upfront Cash : Inapplicable
February 11, 2020
Lead Product(s) : COM902,COM701,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Univo Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Findings suggest use of cannabinoid-based drugs to treat diseases in which there is an overexpression of A3AR including cancer, autoimmune, inflammatory and metabolic diseases.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 16, 2020
Lead Product(s) : Cannabidiol
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Univo Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Orgenesis
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Clinical study will be undertaken with goal of utilizing and validating a number of Orgenesis’ proprietary POCare Technologies, including an automated cell culturing system for the generation and expansion tumor infiltrating lymphocytes for use in adop...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 06, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Orgenesis
Deal Size : Undisclosed
Deal Type : Collaboration